Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus CEFIZOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus CEFIZOX.
CECLOR vs CEFIZOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic